| ID | 117183 |
| 著者 |
板東, 浩
Tokushima University|Japan Low Carbohydrate Diet Promotion Association|Kanaiso Hospital
KAKEN研究者をさがす
Yamashita, H
Kanaiso Hospital
Kato, Y
Kanaiso Hospital
Ogura, K
Kanaiso Hospital
Kato, Y
Kanaiso Hospital
Matsuzaki, S
Kanaiso Hospital
|
| キーワード | semaglutide (Rybelsus)
Semaglutide Treatment Effect in People with Obesity (STEP)
Peptide Innovation for Early diabetes treatment (PIONEER)
glucagon-like-peptide 1 receptor agonist (GLP1-RA)
sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: Latest topic for Type 2 diabetes (T2D) would be oral semaglutide (Rybelsus).
Case presentation: Patient is 74-year-old female with T2D. She showed 65.5 kg (BMI 28.7 kg/m2) and HbA1c 7.4% in Feb 2022. Results: She started Rybelsus 3-7mg/day, and then she had clinical effects as 58kg and 6.0% in June 2022, respectively. Discussion: Rybelsus is characteristic for its clinical efficacy of improvement for glucose variability and body weight. Various data were from Semaglutide Treatment Effect in People with Obesity (STEP) and Peptide Innovation for Early diabetes treatment (PIONEER) studies. This report becomes hopefully useful reference for diabetic research. |
| 掲載誌名 |
International Journal of Endocrinology and Diabetes
|
| ISSN | 26943875
|
| 出版者 | Pubtexto Publishers
|
| 巻 | 5
|
| 号 | 2
|
| 開始ページ | 138
|
| 発行日 | 2022-06-24
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
